title: Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma.
abstract: High-dose interleukin-2 (IL-2) is an available treatment option for patients with metastatic melanoma or renal cell carcinoma, and is associated with sustained complete and partial responses in a subset of patients. IL-2, however, is not devoid of toxicities, most of which involve the cardiovascular system and manifest as hypotension, arrhythmias, and cardiomyopathy. This report describes an unusual presentation of takotsubo cardiomyopathy in a postmenopausal woman receiving high-dose IL-2 for metastatic melanoma.
authors.affiliation: From the Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Senthil
authors.initials: S
authors.lastname: Damodaran
authors.affiliation: From the Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Ewa
authors.initials: E
authors.lastname: Mrozek
authors.affiliation: From the Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: David
authors.initials: D
authors.lastname: Liebner
authors.affiliation: From the Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Kari
authors.initials: K
authors.lastname: Kendra
mesh_terms: D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D054549:Takotsubo Cardiomyopathy / Q000139:chemically induced / Q000473:pathology* / Q000628:therapy
chemical_list: D007376:Interleukin-2